
1. malar j. 2015 oct 9;14:399. doi: 10.1186/s12936-015-0879-9.

significant geographical differences prevalence mutations associated with
plasmodium falciparum plasmodium vivax drug resistance two regions from
papua new guinea.

barnadas c(1)(2)(3), timinao l(4), javati s(5), iga j(6), malau e(7)(8), koepfli 
c(9)(10), robinson lj(11)(12)(13), senn n(14)(15), kiniboro b(16), rare l(17),
reeder jc(18), siba pm(19), zimmerman pa(20), karunajeewa h(21)(22), davis
tm(23), mueller i(24)(25)(26).

author information: 
(1)vector borne diseases unit, papua new guinea institute medical research,
goroka, papua new guinea. barnadas@wehi.edu.au.
(2)population health immunity division, walter eliza hall institute of
medical research, parkville, australia. barnadas@wehi.edu.au.
(3)department medical biology, university melbourne, parkville, vic,
australia. barnadas@wehi.edu.au.
(4)vector borne diseases unit, papua new guinea institute medical research,
goroka, papua new guinea. lincoln.timinao@pngimr.org.pg.
(5)vector borne diseases unit, papua new guinea institute medical research,
goroka, papua new guinea. sarah.javati@pngimr.org.pg.
(6)vector borne diseases unit, papua new guinea institute medical research,
goroka, papua new guinea. jonah.iga@pngimr.org.pg.
(7)population health immunity division, walter eliza hall institute of
medical research, parkville, australia. malau@wehi.edu.au.
(8)department medical biology, university melbourne, parkville, vic,
australia. malau@wehi.edu.au.
(9)population health immunity division, walter eliza hall institute of
medical research, parkville, australia. koepfli@wehi.edu.au.
(10)department medical biology, university melbourne, parkville, vic,
australia. koepfli@wehi.edu.au.
(11)vector borne diseases unit, papua new guinea institute medical research,
goroka, papua new guinea. robinson@wehi.edu.au.
(12)population health immunity division, walter eliza hall institute of
medical research, parkville, australia. robinson@wehi.edu.au.
(13)department medical biology, university melbourne, parkville, vic,
australia. robinson@wehi.edu.au.
(14)vector borne diseases unit, papua new guinea institute medical research,
goroka, papua new guinea. nicolas.senn@gmail.com.
(15)swiss tropical public health institute, basel, switzerland.
nicolas.senn@gmail.com.
(16)vector borne diseases unit, papua new guinea institute medical research,
goroka, papua new guinea. benson.kiniboro@pngimr.org.pg.
(17)vector borne diseases unit, papua new guinea institute medical research,
goroka, papua new guinea. lawrence.rare@pngimr.org.pg.
(18)burnet institute, melbourne, australia. reederj@who.int.
(19)vector borne diseases unit, papua new guinea institute medical research,
goroka, papua new guinea. peter.siba@pngimr.org.pg.
(20)center global health diseases, case western reserve university,
cleveland, usa. paz@case.edu.
(21)population health immunity division, walter eliza hall institute of
medical research, parkville, australia. karunajeewa.h@wehi.edu.au.
(22)department medical biology, university melbourne, parkville, vic,
australia. karunajeewa.h@wehi.edu.au.
(23)school medicine pharmacology, university western australia, perth, 
australia. tim.davis@uwa.edu.au.
(24)population health immunity division, walter eliza hall institute of
medical research, parkville, australia. ivomueller@fastmail.fm.
(25)department medical biology, university melbourne, parkville, vic,
australia. ivomueller@fastmail.fm.
(26)centre de recerca en salut internacional de barcelona, barcelona, spain.
ivomueller@fastmail.fm.

background: drug resistance remains major obstacle malaria treatment and
control. arise spread rapidly, vary substantially even at
sub-national level. national malaria programmes require cost-effective timely
ways characterizing drug-resistance multiple sites within countries.
methods: improved multiplexed post-pcr ligase detection reaction-fluorescent
microsphere assay (ldr-fma) used simultaneously determine presence 
mutations chloroquine resistance transporter (crt), multidrug resistance 1
(mdr1), dihydrofolate reductase (dhfr) dihydropteroate synthase (dhps) genes 
in plasmodium falciparum (n = 727) plasmodium vivax (n = 574) isolates
collected 2006 cross-sectional community population surveys two
geographically distinct regions (madang east sepik) papua new guinea (png)
where strong regional differences vivo aminoquinoline antifolate
therapeutic efficacy previously observed. data compared of
a follow-up survey conducted 2010.
results: despite low parasite densities, assay successfully
amplified p. falciparum p. vivax loci 77 69 % samples,
respectively. 2006, prevalences pfdhfr (59r-108 n) double mutation/wild
type pfdhps haplotype, pfcrt svmnt haplotype (72s-76t double mutation), 86y
pfmdr1 mutation exceeded 90 %. p. vivax, 65 % carried least two pvdhfr
mutations, 97 % 647p pvdhps mutation 54 % 976f pvmdr1 mutation.
prevalence mutant haplotypes higher madang east sepik pfcrt
svmnt (97.4 vs 83.3 %, p = 0.001), pfdhfr (59r-108 n) (100 vs 90.6 %, p = 0.001),
pvdhfr haplotypes (75.8 vs 47.6 %, p = 0.001) pvmdr1 976f (71.2 vs 26.2 %, p 
< 0.001). data subsequent madang survey 2010 showed prevalence
of pfdhps mutations increased significantly <5 % >30 % (p < 0.001) did
the prevalence pvdhfr mutant haplotypes (from 75.8 97.4 %, p = 0.012).
conclusions: ldr-fma multiplex platform shows feasibility low-cost,
high-throughput, rapid characterization broad range drug-resistance
markers low parasitaemia infections. significant geographical differences in
mutation prevalence correlate previous genotyping surveys vivo trials
and may reflect variable drug pressure differences health-care access in
these two png populations.

doi: 10.1186/s12936-015-0879-9 
pmcid: pmc4600278
pmid: 26452541  [indexed medline]

